Kestra Medical Technologies Ltd

Análisis de la acción Kestra Medical Technologies Ltd (KMTS)

$28.320

+1.048 (+3.70%)Al cierre

Loading chart…
Máximo
29.265
Apertura
27.170
Precio medio ponderado por volumen
28.25
Volumen
739.13K
Capitalización
—
Mínimo
27.170
Importe
20.88M
EV/EBITDA, TTM
-7.39

Kestra Medical Technologies, Ltd. is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The Company has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The Company's Cardiac Recovery System platform includes ASSURE WCD, which is a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). Its Cardiac Recovery System platform also includes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services and ASSURE wearable ECG.

Análisis de IA of Kestra Medical Technologies Ltd (KMTS)

Comprar

Kestra Medical Technologies is a good buy right now due to its significant revenue growth of 60% year-over-year, increasing from $19.37 million to $30.97 million, and a gross margin improvement to 56.5%, which is up over 10 percentage points year-over-year. The main risk is the widening net loss of $44.09 million for Q1 2027, which could impact investor sentiment.

Métricas de valoración

El PER previsto actual de Kestra Medical Technologies Ltd (KMTS) es 0.00, frente a su media de 5 años de -9.68.

PER previsto

Muy sobrevalorado
Media 5A P/E
-9.68
P/E actual
0.00
Sobrevalorada
-6.54
Infravalorada
-12.82

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
-10.33
EV/EBITDA actual
-7.39
Sobrevalorada
-4.05
Infravalorada
-16.61

Precio/ventas previsto

Valor razonable
Media 5A P/S
10.75
P/S actual
8.60
Sobrevalorada
14.12
Infravalorada
7.38

Ballenas con KMTS en cartera

J

Jaunty Global Limited

+ Con en carteraKMTS

+1.61%

Rentabilidad a 3 meses

Cronología de eventos

2026-09-15 (ET)

09:00:00

Stock Futures Lower Ahead of Fed Policy Meeting

2026-09-14 (ET)

19:30:00

Anthropic CEO Warns of Out-of-Control AI, Tech Stocks Plunge

17:00:00

Kestra Medical Shares Down 7% to $22.32 After Q1 Earnings Miss

16:30:00

Kestra Reports Q1 Revenue of $30.97M, Exceeding Expectations

16:30:00

Kestra Raises FY27 Revenue Guidance to $141 Million

Noticias

Preguntas frecuentes sobre KMTS, respondidas por Alphio AI

Kestra Medical Technologies, Ltd. is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The Company has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The Company's Cardiac Recovery System platform includes ASSURE WCD, which is a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). Its Cardiac Recovery System platform also includes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services and ASSURE wearable ECG. It operates in the Healthcare sector.

Kestra Medical Technologies is a good buy right now due to its significant revenue growth of 60% year-over-year, increasing from $19.37 million to $30.97 million, and a gross margin improvement to 56.5%, which is up over 10 percentage points year-over-year. The main risk is the widening net loss of $44.09 million for Q1 2027, which could impact investor sentiment.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar